Can India's National Medical Devices Policy Unleash Sector's Full Potential?
BioSpectrum Asia|BioSpectrum Asia June 2023
The National Medical Devices Policy, 2023 that got the approval of the government of India on April 26 seems to have made the medical devices sector happy. The slew of strategies mentioned in the policy assures a win–win outcome for the manufacturers as well as patients. Experts are upbeat about the projected growth of the sector in the near future. The policy aims to bring a range of interventions in a coherent manner that would facilitate focussed and efficient support and facilitation for the sector by the respective agencies. Let’s explore further.
Sanjiv Das
Can India's National Medical Devices Policy Unleash Sector's Full Potential?

The medical devices sector was nothing short of thanking the government of India for the recently announced approved policy National Medical Devices Policy, 2023 by the Union Cabinet, chaired by the Prime Minister of India Narendra Modi. The policy is expected to help the medical devices sector to grow from present $11 billion to $50 billion in next five years. It is being touted by experts in the medical devices sector as a positive step where the industry is likely to become Atmanirbhar which will help to make affordable high quality and safe medical devices accessible to the world. This Policy will be in addition to the existing Production Linked Incentive (PLI) schemes that are underway.

Notably, till the recent 2023 Budget, the sector wasn’t all too pleased with the government’s position, as nothing substantial was announced for the sector. The sector had been seeking reforms since the past few years and ultimately it can now heave a sigh of relief.

Key focus areas

The current policy aims to put in place a comprehensive set of focus areas for the growth of the sector in a coordinated manner. The policy aims to bring a range of interventions in a coherent manner that would facilitate focussed and efficient support and facilitation for the sector by the respective agencies.

Diese Geschichte stammt aus der BioSpectrum Asia June 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der BioSpectrum Asia June 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BIOSPECTRUM ASIAAlle anzeigen
Inventia announces groundbreaking advancement in 3D cell culture technology
BioSpectrum Asia

Inventia announces groundbreaking advancement in 3D cell culture technology

Inventia Life Science, an innovator in 3D cell culture technologies, has announced the launch of RASTRUM Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug discovery and disease research with unprecedented scalability, reproducibility, and efficiency.

time-read
1 min  |
March 2025
Aphra names Justin Untersteiner as CEO
BioSpectrum Asia

Aphra names Justin Untersteiner as CEO

The Australian Health Practitioner Regulation Agency (Ahpra) has appointed Justin Untersteiner as Chief Executive Officer (CEO).

time-read
1 min  |
March 2025
WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls
BioSpectrum Asia

WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls

The World Health Organization (WHO) has signed a Memorandum of Understanding (MoU) with Siriraj Hospital, Mahidol University, Thailand, to strengthen collaboration on trauma, injury, and fall prevention across the WHO South-East Asia Region to address the growing health, social, and economic challenges posed by these issues.

time-read
1 min  |
March 2025
Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services
BioSpectrum Asia

Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services

Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre (PF) SA, and its affiliate entities, for JBIRSPL to acquire 80 per cent equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20 per cent retained by PF.

time-read
1 min  |
March 2025
PanopticAI gets US FDA clearance for contactless vital signs monitoring software
BioSpectrum Asia

PanopticAI gets US FDA clearance for contactless vital signs monitoring software

PanopticAI, a startup in remote patient monitoring space, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its contactless vital signs monitoring software.

time-read
1 min  |
March 2025
Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma
BioSpectrum Asia

Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics has unveiled Qartemi, country’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a group of blood cancers.

time-read
1 min  |
March 2025
Axel Klarmeyer joins as CEO at Chamlion International
BioSpectrum Asia

Axel Klarmeyer joins as CEO at Chamlion International

China-based Chamlion, a pioneer in integrated dental 3D printing solutions, has announced the appointment of Axel Klarmeyer as the Chief Executive Officer (CEO) of Chamlion International, overseeing the company's international business operations.

time-read
1 min  |
March 2025
World Bank supports Bosnia and Herzegovina in strengthening healthcare
BioSpectrum Asia

World Bank supports Bosnia and Herzegovina in strengthening healthcare

The World Bank’s Board of Executive Directors has approved a $75 million Second Health Sectors Programmatic Development Policy Loan for Bosnia and Herzegovina (BiH).

time-read
1 min  |
March 2025
GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs
BioSpectrum Asia

GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs

The Global Health Innovative Technology (GHIT) Fund, headquartered in Japan, has announced a total investment of approximately JPY 2 billion ($12.7 million) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.

time-read
1 min  |
March 2025
NIH to lead implementation of National Plan to End Parkinson's Act in US
BioSpectrum Asia

NIH to lead implementation of National Plan to End Parkinson's Act in US

With support from the US Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH), the National Institutes of Health (NIH) is leading the implementation of the Dr. Emmanuel Bilirakis and Jennifer Wexton National Plan to End Parkinson’s Act, which was signed into law on July 2, 2024.

time-read
1 min  |
March 2025